Know Cancer

forgot password

Cancer Risk in Xeroderma Pigmentosum Heterozygotes

Open (Enrolling)
Xeroderma Pigmentosum

Thank you

Trial Information

Cancer Risk in Xeroderma Pigmentosum Heterozygotes

Xeroderma Pigmentosum (XP) is a rare, recessive disorder with a more than 1000-fold increase
in the frequency of all major skin cancers in association with defective DNA repair. The
risk of skin and other cancers among normal appearing XP heterozygote individuals has not
been fully studied. We plan to study the family members from XP families with known DNA
repair gene mutations to determine if heterozygote carriers of XP disease mutations are at
an increased risk of developing cancer. For controls we will compare XP heterozygotes to
their non-carrier blood relatives and spouses and to the Surveillance, Epidemiology and End
Results (SEER) rates. For this purpose, blood, skin or buccal cells will be obtained from
all available relatives for DNA or RNA mutation analysis. Cancer confirmation will be
accomplished through review of pathology reports, medical records and death certificates. In
addition, willing family members will be examined to determine current cancer status.
Individuals who are determined to be heterozygous carriers of XP DNA repair gene disease
mutations in these families by mutation analysis or by pedigree will be compared to
non-carrier relatives and spouses with respect to history of any type of cancer. We will
also focus on skin cancer and cancer of the nervous system since the risks of these cancers
are elevated among the XP homozygotes.

Inclusion Criteria


Members of the XP families where the proband has previously been evaluated at the Clinical
Center or is newly diagnosed under other approved protocols (primarily 99-C-0099) are
eligible to participate in this study. Families with XP patients of any age, gender or
race are eligible for this study.

On referral, families of XP patients will be considered for inclusion in the study if the
proband has clinical documentation of features of XP and laboratory determination of the
DNA repair defect. All relatives of XP patients including spouses are eligible to


Inability or unwillingness to provide family history information or tissue (skin, blood,
buccal cells or hair) for laboratory studies.

Type of Study:


Study Design:


Principal Investigator

Kenneth H Kraemer, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)


United States: Federal Government

Study ID:




Start Date:

September 2002

Completion Date:

Related Keywords:

  • Xeroderma Pigmentosum
  • DNA Repair
  • Molecular Epidemiology
  • Skin Cancer
  • Genetics
  • Melanoma
  • Xeroderma Pigmentosum
  • XP
  • Ichthyosis
  • Xeroderma Pigmentosum



National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland  20892